Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

asbury carbons

POPULAR ARTICLES

Types of Graphite: Amorphous, Flake and Vein

Graphite Investing

Types of Graphite: Amorphous, Flake and Vein

Graphite Investing

Graphite Investing

Stephen Riddle: The Natural Flake Graphite Market is a “Buyer’s Market” Right Now

Graphite Investing

Graphite Investing

Benchmark Minerals Week: Graphite+Anodes Notes from the Floor

LATEST ARTICLES

ASX:SYR

Graphite Investing

Graphite Outlook 2017: Will the Market Take Off?

Benchmark's Andrew Miller Talks Graphite Prices and China

Graphite Investing

Benchmark's Andrew Miller Talks Graphite Prices and China

Graphite Investing

Graphite Outlook 2015: Tesla and LG Chem to be ‘Catalysts for Everything’

Graphite Investing

Stephen Riddle: What Investors Really Need to Know About Graphite

Graphite Investing

Canada Carbon’s Miller Project Attracting Analyst Attention

Asbury Carbons Increases Competitiveness in Europe

Graphite Investing

Great Lakes Graphite: Not Your Average Exploration Company

Graphite Investing

Powering the Future: 5 Graphite Juniors Talk Demand and Tesla’s Gigafactory

Graphite Investing

PROJECT UPDATE: Saint Jean Carbon Enters Synthetic Graphite Distribution Agreement

Graphite Investing

Simon Moores Talks Prices and “Serious” Graphite Companies

Zenyatta Clarifies Geology, Metallurgy of Graphite Discovery

Graphite Investing

Zenyatta Pins Hopes on Hydrothermal Graphite Deposit

Latest News

AMERICAN SALARS ADDS LITHIUM BRINE EXPERT DR. MARK KING AS A TECHNCIAL ADVISOR AND QUALIFIED PERSON

SCRi Reports 8th Consecutive Quarter Revenue Growth and Provides Corporate Update

SAGA Metals Appoints Vernon Shein, Former Exploration Manager at B2Gold, to its Board of Advisors

EL2780 Award – New Targets from Airborne MT

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone